Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr Judith Balmaña
Dr Rebecca Dent
Prof. Simon Boulton
Prof. Sibylle Loibl
Prof. Eric Pujade-Lauraine
Prof. Charlie Gourley
Dr Violeta Serra
Prof. Jonathan A. Ledermann
Publication Date
Sep 2021
Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca.
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Artios Pharma Ltd.
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca and Tesaro.
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
Programme summary
Duration 10 MIN
Downloadable resources Yes-
DOWNLOAD THE SLIDES
-
Language(s)
Share this programme
Other programmes of interest
Podcast
Episode
4
of 4
Oncology
HCC podcast series part 4: Intermediate HCC – the evolving role of IO
Integrating multimodal approaches with multidisciplinary care
Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)Endorsed by
-
Downloadable
Resources -
27 MIN
-
Jan 2025
Video
Oncology
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer
Exploring the impact of liquid biopsy in advanced breast cancer
Experts
Prof. Frédérique Penault-Llorca, Dr Aditya BardiaEndorsed by
-
Downloadable
Resources -
6 MIN
-
Jan 2025
Animated Video
Oncology Obstetrics and Gynecology
Current treatment options in advanced/recurrent endometrial cancer
Exploring the impact of molecular subtypes
Experts
Prof. Christian Marth-
Downloadable
Resources -
7 MIN
-
Jan 2025
Podcast
Episode
3
of 4
Oncology
HCC podcast series part 3: Intermediate HCC – treatment options and strategies
Expert insights on systemic, loco-regional, and multimodal therapies
Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)Endorsed by
-
Downloadable
Resources -
20 MIN
-
Jan 2025
Video
Oncology
Recent advances in precision oncology and future implications
Two emerging and two established targets
Experts
Prof. David Hong-
Downloadable
Resources -
4 MIN
-
Dec 2024
Publication
Oncology
Survey on the evolving role of the oncology nurse in the USA
Announcing the publication of survey results
Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo-
Downloadable
Resources -
10 MIN
-
Dec 2024
